

04/26/2017

Revolutionary Medical Devices, Inc. Announces Grant US Patent 9,629,975 For Use of SuperNO₂VA Et™ Mask

TUCSON, AZ – April 26, 2017– Revolutionary Medical Devices, Inc. (RMD) announces that on April 25, 2017, the United States Patent and Trademark Office (USPTO) granted US Patent 9,629,975 (the '975 patent) directed to the use of RMD's SuperNO₂VA Et™ Mask.

At the PGA70 PostGraduate Assembly in Anesthesiology in December 2016, RMD introduced the SuperNO₂VA Et™ Mask. The SuperNO₂VA Et™ Mask is the first nasal ventilation mask designed to support oral and nasal End-tidal CO₂ (EtCO₂) sampling.

EtCO₂ is the partial pressure or maximal concentration of carbon dioxide (CO₂) at the end of an exhaled breath. Carbon dioxide monitoring, defined as *capnography*, is already a standard of care in anesthesia practice to monitor and document ventilation during sedation and general anesthetics, and is an emerging standard in emergency medical services, emergency medicine, and intensive care patient treatment. The SuperNO₂VA Et™ Mask has specially designed features for capturing nasally or orally-exhaled CO₂ that are not in prior nasal ventilation masks.

The SuperNO₂VA Et™ Mask samples nasally-exhaled CO₂ from directly within the mask while simultaneously measuring orally-exhaled CO₂ via its Exhalation Hood feature. The Exhalation Hood is formed of a flexible material that overlies the patient's upper lip to catch and direct the patient's orally-exhaled breath. This Hood can also be compressed or folded back on itself to provide, when needed, unrestricted oral access to the patient—such as when the patient undergoes laryngoscopy, endoscopy, or fiberoptic bronchoscopy.

“In the field of nasal masks, the SuperNO₂VA Et™ Mask is pioneering. It is designed to sample EtCO₂ simultaneously from a patient's nasal and oral pathways with its specially-designed Exhalation Hood,” said David Kane, President and CEO of RMD. He added, “We are pleased to have an exclusive position as to this pioneering mask technology through the '975 patent. With many pending patent applications, we expect this will be the first of many patents granted to RMD.”

About RMD

Revolutionary Medical Devices, Inc. (RMD), a market innovator and leader in nasal ventilation during anesthesia, develops, manufactures, and markets innovative medical products and services to the healthcare industry. RMD is committed to significantly improving patient outcomes from anesthesia. RMD products are being designed to combat the complications and costs associated with sedation-related respiratory compromise. To learn more about RMD, visit <http://rmdevices.com/>.

This document contains forward-looking statements that involve risks and uncertainties and opinions and beliefs of management. Any statements (including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “are of the opinion” and similar expressions) that are not

statements relating to historical matters should be considered forward-looking statements and should not be relied upon as factual or certain. Actual results may differ materially from the results discussed in the forward-looking statements as a result of numerous important risk factors. These assumptions are subject to uncertainties inherent in the forecasts and there will usually be differences between the forecasted and actual results because events and circumstances frequently do not occur as expected and those differences may be material.

#

For more information about this topic or to schedule an interview with Dave Kane, CEO of RMD, please contact Kristine Kurilko, VP Sales & Marketing, at 856-906-2902 or kristine.kurilko@rmdevices.com.